Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography

Multiple Sclerosis Journal

Volumn 21, Issue 6, 2015, Pages 678-688

  Bennett, J L ^a   de Seze, J ^b   Lana Peixoto, M ^c   Palace, J ^d   Waldman, A ^e   Banwell, B ^e   Schippling, S ^f   Tenembaum, S ^g   Greenberg, B ^h   Levy, M ⁱ   Fujihara, K ^j   Chan, K H ^k   Kim, H J ^l   Asgari, N ^m   Sato, D K ⁿ   Saiz, A ^o   Villoslada, P ^p   Zimmermann, H ^q   Wuerfel, J ^q   Green, A ^r   Paul, F ^q   more..

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c UNIVERSITY OF MINAS GERAIS   (Brazil)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g Hospital de Pediatria SAMIC Prof Dr Juan P Garrahan   (Argentina)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k UNIVERSITY OF HONG KONG   (Hong Kong)

^l National Cancer Center   (South Korea)

^m UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

ⁿ TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^p HOSPITAL CLÍNIC   (Spain)

^q CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^r UCSF Multiple Sclerosis Center   (United States)

more..

Author keywords

ganglion cell layer; multiple sclerosis; Neuromyelitis optica; optic neuritis; optical coherence tomography; retinal nerve fiber layer

Indexed keywords

HUMAN; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PROCEDURES; RETINA NERVE CELL; ULTRASTRUCTURE; ANTIBODY BLOOD LEVEL; BRAIN SIZE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE DURATION; DRUG MEGADOSE; MACULAR EDEMA; MYELOOPTIC NEUROPATHY; OPHTHALMOSCOPY; PLASMAPHERESIS; RETINA GANGLION CELL; RETINA INJURY; RETINAL NERVE FIBER LAYER THICKNESS; REVIEW; SYSTEMATIC REVIEW; THERAPY EFFECT; VISUAL ACUITY; VISUAL SYSTEM FUNCTION;

HUMANS; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; OPTIC NEURITIS; RETINAL NEURONS; TOMOGRAPHY, OPTICAL COHERENCE;

AQUAPORIN 4; AUTOANTIBODY; CORTICOSTEROID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE;

EID: 84961289267     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514567216     Document Type: Review

References (80)

1. Wingerchuk DM, Hogancamp WF, O’Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107–1114.
2. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473–477.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004; 364: 2106–2112.
4. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805–815.
5. Papadopoulos MC, Verkman A. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012; 11: 535–544.
6. Tzartos JS, Stergiou C, Kilidireas K, et al. Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders. PLoS One 2013; 8: e74773.
7. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012; 135: 1834–1849.
8. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82: 474–481.
9. Frohman EM, Fujimoto JG, Frohman TC, et al. Optical coherence tomography: A window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol 2008; 4: 664–675.
10. Bertuzzi F, Suzani M, Tagliabue E, et al. Diagnostic validity of optic disc and retinal nerve fiber layer evaluations in detecting structural changes after optic neuritis. Ophthalmology 2010; 117: 1256–1264.e1.
11. Zaveri MS, Conger A, Salter A, et al. Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis. Arch Neurol 2008; 65: 924–928.
12. Frohman E, Costello F, Zivadinov R, et al. Optical coherence tomography in multiple sclerosis. Lancet Neurol 2006; 5: 853–863.
13. Saidha S, Syc SB, Durbin MK, et al. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult Scler 2011; 17: 1449–1463.
14. Chen TC, Zeng A, Sun W, et al. Spectral domain optical coherence tomography and glaucoma. Int Ophthalmol Clin 2008; 48: 29–45.
15. Bock M, Brandt AU, Dörr J, et al. Time domain and spectral domain optical coherence tomography in multiple sclerosis: A comparative cross-sectional study. Mult Scler 2010; 16: 893–896.
16. Kallenbach K, Frederiksen J. Optical coherence tomography in optic neuritis and multiple sclerosis: A review. Eur J Neurol 2007; 14: 841–849.
17. Sepulcre J, Murie-Fernandez M Salinas-Alaman A, et al. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology 2007; 68: 1488–1494.
18. Oberwahrenbrock T, Schippling S, Ringelstein M, et al. Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int 2012; 2012: 530305.
19. Oberwahrenbrock T, Ringelstein M, Jentschke S, et al. Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler 2013; 19: 1887–1895.
20. Frohman EM, Frohman TC, Zee DS, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005; 4: 111–121.
21. Tsoi VL, Hill KE, Carlson NG, et al. Immunohistochemical evidence of inducible nitric oxide synthase and nitrotyrosine in a case of clinically isolated optic neuritis. J Neuroophthalmol 2006; 26: 87–94.
22. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70: 2197–2200.
23. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130: 1194–1205.
24. Asavapanumas N, Ratelade J, Papadopoulos MC, et al. Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G. J Neuroinflammation 2014; 11: 16.
25. Hofman P, Hoyng P, van der Werf F, et al. Lack of blood-brain barrier properties in microvessels of the prelaminar optic nerve head. Invest Ophthalmol Vis Sci 2001; 42: 895–901.
26. Liu LY, Zheng H, Xiao HL, et al. Comparison of blood-nerve barrier disruption and matrix metalloprotease-9 expression in injured central and peripheral nerves in mice. Neurosci Lett 2008; 434: 155–159.
27. Matiello M, Schaefer-Klein J Sun D, et al. Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica. JAMA Neurol 2013; 70: 1118–1125.
28. Merle H, Olindo S, Bonnan M, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 2007; 114: 810–815.e2.
29. Kitley JL, Leite M, Matthews LE, et al. Use of mitoxantrone in neuromyelitis optica. Arch Neurol 2011; 68: 1086–1087.
30. Fernandes DB, Ramos R, de IP Falcochio C, et al. Comparison of visual acuity and automated perimetry findings in patients with neuromyelitis optica or multiple sclerosis after single or multiple attacks of optic neuritis. J Neuroophthalmol 2012; 32: 102–106.
31. Merle H, Olindo S, Jeannin S, et al. Visual field characteristics in neuromyelitis optica in absence of and after one episode of optic neuritis. Clin Ophthalmol 2013; 7: 1145–1153.
32. Pfueller CF, Paul F. Imaging the visual pathway in neuromyelitis optica. Mult Scler Int 2011; 2011: 869814.
33. Khanna S, Sharma A, Huecker J, et al. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol 2012; 32: 216–220.
34. Storoni M, Davagnanam I, Radon M, et al. Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: A novel magnetic resonance imaging scoring system. J Neuroophthalmol 2013; 33: 123–127.
35. Parisi V, Manni G, Spadaro M, et al. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci 1999; 40: 2520–2527.
36. Petzold A, de Boer JF Schippling S, et al. Optical coherence tomography in multiple sclerosis: A systematic review and meta-analysis. Lancet Neurol 2010; 9: 921–932.
37. Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006; 113: 324–332.
38. Henderson AP, Trip SA, Schlottmann PG, et al. A preliminary longitudinal study of the retinal nerve fiber layer in progressive multiple sclerosis. J Neurol 2010; 257: 1083–1091.
39. Talman LS, Bisker ER, Sackel DJ, et al. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol 2010; 67: 749–760.
40. Saidha S, Syc SB, Ibrahim MA, et al. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain 2011; 134 (Pt 2): 518–533.
41. Levin MH, Bennett JL, Verkman AS. Optic neuritis in neuromyelitis optica. Prog Retin Eye Res 2013; 36: 159–171.
42. Ratchford JN, Quigg ME, Conger A, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 2009; 73: 302–308.
43. Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology 2009; 72: 1077–1082.
44. Green AJ, Cree BA. Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. J Neurol Neurosurg Psychiatry 2009; 80: 1002–1005.
45. Nakamura M, Nakazawa T, Doi H, et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1777–1785.
46. de Seze J Blanc F Jeanjean L, et al. Optical coherence tomography in neuromyelitis optica. Arch Neurol 2008; 65: 920–923.
47. Merle H, Olindo S, Donnio A, et al. Retinal peripapillary nerve fiber layer thickness in neuromyelitis optica. Invest Ophthalmol Vis Sci 2008; 49: 4412–4417.
48. Lange AP, Sadjadi R, Zhu F, et al. Spectral-domain optical coherence tomography of retinal nerve fiber layer thickness in NMO patients. J Neuroophthalmol 2013; 33: 213–219.
49. Gelfand JM, Cree BA, Nolan R, et al. Microcystic inner nuclear layer abnormalities and neuromyelitis optica. JAMA Neurol 2013; 70: 629–633.
50. Schneider E, Zimmermann H, Oberwahrenbrock T, et al. Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PloS One 2013; 8: e66151.
51. Fernandes DB, Raza AS, Nogueira RG, et al. Evaluation of inner retinal layers in patients with multiple sclerosis or neuromyelitis optica using optical coherence tomography. Ophthalmology 2013; 120: 387–394.
52. Bouyon M, Collongues N, Zéphir H, et al. Longitudinal follow-up of vision in a neuromyelitis optica cohort. Mult Scler 2013; 19: 1320–1322.
53. Bock M, Brandt AU, Dörr J, et al. Patterns of retinal nerve fiber layer loss in multiple sclerosis patients with or without optic neuritis and glaucoma patients. Clin Neurol Neurosurg 2010; 112: 647–652.
54. Monteiro MLR, Fernandes DB, Apóstolos-Pereira SL, et al. Quantification of retinal neural loss in patients with neuromyelitis optica and multiple sclerosis with or without optic neuritis using Fourier-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2012; 53: 3959–3966.
55. Syc SB, Saidha S, Newsome SD, et al. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain 2012; 135: 521–533.
56. Sotirchos ES, Saidha S, Byraiah G, et al. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology 2013; 80: 1406–1414.
57. Park KA, Kim J, Oh SY. Analysis of spectral domain optical coherence tomography measurements in optic neuritis: Differences in neuromyelitis optica, multiple sclerosis, isolated optic neuritis and normal healthy controls. Acta Ophthalmol 2014; 92: e57–e65.
58. Kaufhold F, Zimmermann H, Schneider E, et al. Optic neuritis is associated with inner nuclear layer thickening and microcystic macular edema independently of multiple sclerosis. PLoS One 2013; 8: e71145.
59. Ringelstein M, Kleiter I, Ayzenberg I, et al. Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Mult Scler 2014; 20: 617–620.
60. Gelfand JM, Nolan R, Schwartz DM, et al. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain J Neurol 2012; 135 (Pt 6): 1786–1793.
61. Saidha S, Sotirchos ES, Ibrahim MA, et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: A retrospective study. Lancet Neurol 2012; 11: 963–972.
62. Brandt AU, Oberwahrenbrock T, Kadas EM, et al. Dynamic formation of macular microcysts independent of vitreous traction changes. Neurology 2014; 83: 73–77.
63. George J, Kitley J, Leite M, et al. Microcystic inner nuclear layer pathology in aquaporin-4 antibody-positive patients. Poster In: 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS). Copenhagen, Denmark, 2–5 October 2013.
64. Albrecht P, Fröhlich R Hartung HP, et al. Optical coherence tomography measures axonal loss in multiple sclerosis independently of optic neuritis. J Neurol 2007; 254: 1595–1596.
65. Toledo J, Sepulcre J, Salinas-Alaman A, et al. Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. Mult Scler 2008; 14: 906–912.
66. McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008; 71: 93–100.
67. Li Q, Timmers AM, Hunter K, et al. Noninvasive imaging by optical coherence tomography to monitor retinal degeneration in the mouse. Invest Ophthalmol Vis Sci 2001; 42: 2981–2989.
68. Horio N, Kachi S, Hori K, et al. Progressive change of optical coherence tomography scans in retinal degeneration slow mice. Arch Ophthalmol 2001; 119: 1329–1332.
69. Grieve K, Paques M, Dubois A, et al. Ocular tissue imaging using ultrahigh-resolution, full-field optical coherence tomography. Invest Ophthalmol Vis Sci 2004; 45: 4126–4131.
70. Zimmermann H, Freing A, Kaufhold F, et al. Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. Mult Scler 2013; 19: 443–450.
71. Dörr J Wernecke KD Bock M, et al. Association of retinal and macular damage with brain atrophy in multiple sclerosis. PloS One 2011; 6: e18132.
72. Young KL, Brandt AU, Petzold A, et al. Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis. Eur J Neurol 2013; 20: 803–811.
73. von Glehn F Jarius S Cavalcanti Lira RP, et al. Structural brain abnormalities are related to retinal nerve fiber layer thinning and disease duration in neuromyelitis optica spectrum disorders. Mult Scler 2014; 20: 1189–1197.
74. Kim SH, Kim W, Li XF, et al. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler 2012; 18: 1480–1483.
75. Palace J, Leite M, Nairne A, et al. Interferon beta treatment in neuromyelitis optica: Increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010; 67: 1016–1017.
76. Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: Multicenter study of treatment efficacy. JAMA Neurol 2014; 71: 324–330.
77. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012; 69: 239–245.
78. Merle H, Olindo S, Jeannin S, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol 2012; 130: 858–862.
79. Khatri BO, Kramer J, Dukic M, et al. Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica. J Clin Apheresis 2012; 27: 183–192.
80. Sühs KW, Hein K Sättler MB, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 2012; 72: 199–210.